BSA
ALT icon

Braun Stacey Associates’s Altimmune ALT Stock Holding History

Braun Stacey Associates’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-711,818
Closed -$8.05M – 131
2021
Q3 		$8.05M Buy
711,818
+2,890
+0.4% +$35.1K 0.32% 100
2021
Q2 		$6.98M Buy
+708,928
New +$9.69M 0.27% 102

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Braun Stacey Associates's ALT Position: Q4 2021 in Review

Braun Stacey Associates sold out of Altimmune (ALT) in Q4 2021, closing a stake of 711,818 shares — an estimated $8.05M sold.

Braun Stacey Associates first reported a position in ALT in Q2 2021 and held it in 2 quarters. The position peaked at $8.05M in Q3 2021. 102 funds tracked by Wall St. Rank hold ALT as of Q4 2021.

  • Braun Stacey Associates reported no remaining Altimmune position as of Q4 2021 after selling out during the quarter.
  • Braun Stacey Associates sold 711,818 Altimmune shares in Q4 2021, an estimated $8.05M.
  • Braun Stacey Associates first reported a position in Altimmune in Q2 2021 and held it in 2 quarters.
  • Braun Stacey Associates's Altimmune position peaked at $8.05M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Altimmune as of Q4 2021.

Based on Braun Stacey Associates's 13F filing for Q4 2021, filed 25 Jan 2022.